A Review on FDA Approval of Lymphoma Drug Ukoniq (Umbralisib) And Its Withdrwal Due to Safety Concerns . Journal of Pharmaceutical Negative Results [Internet]. 2022 Dec. 11 [cited 2026 Jun. 23];13(4):1465-74. Available from: https://www.pnrjournal.com/index.php/home/article/view/4551